Salvador Payán Pernía: Arguing against a Significant Role for Erythropoietin Analogues in the Management of PRCA
Salvador Payán Pernía, Member of the Board of Directors of the Erythropathology Group at Spanish Society of Hematology and Hemotherapy (SEHH), shared on LinkedIn about a recent article he and his co-authord, published in Blood Advances, adding:
“I’m delighted to have contributed to this European multicentre study on acquired pure red cell aplasia (PRCA), one of the rare diseases I most enjoy managing.
Acquired PRCA is an underrecognized entity, even among hematologists, as reflected by the median time from presentation to treatment of 2 months (range: 1–204 months) observed in our study.
PRCA should be promptly suspected in any patient with severe anemia and a low reticulocyte count. In our study, earlier initiation of cyclosporine A was associated with a better response.
Our study also shows that PRCA is characterized by markedly elevated erythropoietin levels (median: 908 mIU/mL; range: 29–3000 mIU/mL), likely related to reduced degradation by erythroblasts.
These findings argue against a significant role for erythropoietin analogues in the management of PRCA.
At diagnosis, most patients had elevated ferritin levels and transferrin saturation, reflecting rapid iron accumulation and reduced iron utilization.
Reticulocytes are crucial not only for diagnosis but also as an early marker of response, as highlighted in the paper –look at the reticulocytes!
Thanks to Bruno Fattizzo and Francesco Versino for their initiative, leadership, and excellent work.”
Title: Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study
Authors: Francesco Versino,Marc Michel,Jennifer Vidler, Salvador Payán-Pernía,Roochi Trikha,Shreyans A Gandhi,Sukanya Gogoi,Manujasr, Wimalachandra,Omar Racchi,Maria Teresa Lupo-Stanghellini,Sabrina Giammarco,Maria Arguello Marina,Mara Memoli,Andreas Glenthøj,Gabriele Merati, Yamuna Wasanthi Wickramasinghe,Aparna Chitharanjan,Mylene Hemmer,Mariasanta Napolitano,Margarita Jimenez-Jambrina,Filippo Brioschi, Antonio Palma-Vallelano,Tomas Jose Gonzalez-Lopez,Cristina Clissa,Marta Bortolotti,Giacinto Luca Pedone,Giorgio Alberto Croci,Francesco Passamonti, Wilma Barcellini, Austin G Kulasekararaj, Bruno Fattizzo
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 24, 2026, 16:57Pall T. Onundarson: Fiix Prothrombin Time Advancing Precision in Anticoagulation Management
-
Oct 24, 2026, 16:42Mark-Anthony Johnson: Blood Type Awareness and Emergency Transfusion
-
Oct 24, 2026, 16:27Pedro Perez: Florida’s Push to Strengthen VTE Prevention
-
Oct 24, 2026, 16:23Kathleen Freson: Human Cell Models Advance Research into Rare Platelet Disorders
-
Oct 24, 2026, 16:18Victor Daniel: Deep Learning for Automated Platelet Classification
-
Oct 24, 2026, 16:08Paula Alonso-Frías: Human Umbilical Cord Blood Platelet-Rich Plasma for Endometrial Regeneration
-
Oct 24, 2026, 16:00Fatma Ebeid: Ain Shams University Hosts TIF Experts for Collaborating Center Evaluation
-
Oct 24, 2026, 15:52Mazen A. Juratli: Platelet-Derived Extracellular Vesicles as Potential Predictors of Survival in Liver Cancer
-
Oct 24, 2026, 14:28Satyam Arora: Umbilical Cord Blood for Neonatal Transfusions